Durable Responses Move Kite Toward Pivotal Trial For CAR T-Cell Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Kite hopes to begin a registrational trial for KTE-C19 in diffuse large B-cell lymphoma by 2015, file a BLA in 2016 and launch the first chimeric antigen receptor T-cell therapy for cancer by 2017. Results from a Phase I/II trial being conducted by the National Cancer Institute show ongoing remissions up to 22 months in patients with very short life expectancies.